Literature DB >> 28588935

The Internet of Things to come: digital technologies and the End TB Strategy.

Dennis Falzon1, Mario Raviglione1.   

Abstract

Entities:  

Year:  2016        PMID: 28588935      PMCID: PMC5321338          DOI: 10.1136/bmjgh-2016-000038

Source DB:  PubMed          Journal:  BMJ Glob Health        ISSN: 2059-7908


× No keyword cloud information.
In his prescient novel of 1933—The Shape of Things to Come—the English writer H.G. Wells described the years from 1978 to 2059 as a time of profound social change, reinforced structures of global control and close scrutiny of human activity, as efforts united towards the creation of a utopian World State.1 From a global health perspective, the past four decades have clearly left an indelible mark. The Alma Ata declaration of 1978 heralded a worldwide shift in decentralisation of healthcare and empowerment of communities.2 The international mobilisation to address major epidemics like AIDS, vector-borne diseases and tuberculosis bore dividends. And, digital technology has facilitated epidemiological studies, research and effective advocacy through culturally appropriate social marketing techniques. Building on such successes in the face of future challenges and opportunities will require continued concerted action if public health concerns such as tuberculosis are to be consigned to history. In 2014, the World Health Assembly resolved to end the tuberculosis epidemic in the 20 years following 2015.3 The implementation of this ‘End TB Strategy’ will require new approaches to prevent and treat the disease, including broad-scale action on poverty and determinants of tuberculosis, aligned fully with the United Nations' Sustainable Development Goals (SDGs).4 This implies a change in the values that governed anti-tuberculosis (TB) interventions until 2015. The ‘all-of-government’ approach to public health has to devolve to a larger ‘all-of-society’ base. The primacy of cost in priority-setting, imposed by successive years of financial adversity, needs to yield to more holistic precepts. These include the moral and solidarity principles posed by a largely curable disease which is often fatal, and the negative impact of wasted resources and polluting activities on the environment, key considerations underpinning the SDGs. These changes will require ‘disruptive’ thinking to make the leap from wish to reality. How well we can leverage digital technologies and mould them to our needs could determine whether we will reach such goals or not. There is little new about employing information and communication technology (ICT) in the fight against tuberculosis: WHO has been supporting the use of ICT in surveillance, patient care, programme management, advocacy and eLearning for some time.5 Electronic databases to manage patient records are being widely deployed in low-resource settings;6 educational material for lay persons and professionals is available on many internet sites; and patients and caregivers increasingly maintain contact via text and voice over the ubiquitous mobile phone as telephone and internet coverage expand globally. Very often, however, these endeavours fail to take advantage of the full potential of existing technology and the benefits of large-scale implementation:7 when measured against what the most basic forms of online banking and airline ticket booking services offer in terms of efficiency, consistency and completeness, their performance pales miserably. Such weaknesses will persist until decision-makers and entrepreneurs become convinced of the opportunities missed when access to good-quality data is patchy or absent. Frequently, what restrains access are defects in the supporting structures which would long have been fixed had a profit motive been more evident! Sound investment cases are needed to get open standards for health data coding and exchange more broadly applied, and to have information systems created to interoperate from the moment of their inception across a broad range of health conditions and interrelated sectors—laboratory, pharmacy, imaging, genomics and clinics. The digital health landscape is poised to be transformed, opening unprecedented opportunities for public health action (table 1). Just as remote sensing today allows security cameras, heating systems and refrigerators to communicate with household owners, sensors embedded in ‘wearables’ or within ingested ‘smart pills’ could provide an intimate level of biological monitoring—such as blood levels of medication and biomarkers of disease activity—which can maximise therapeutic effectiveness. This Internet of Things (IOT) is touted to become a game changer in the field of diagnostics, personalised care and public health.8 For it to materialise, it would require an expanded capacity to interpret live data in the light of the variety and the massive volumes by which historical records are being generated by processes in healthcare, retail, finance, leisure and the social media networks with which individuals interact. There is a growing appreciation of how ‘Big Data’ could contribute to operational intelligence, helping users make better-informed decisions,9 eliminate the language barrier in communication, reward healthier behaviour and cut down on waste, unnecessary travel and inconvenience. Moreover, hardware like digital spirometers and nano-biosensors linked to smartphones can allow specialist opinion to reach all levels of clinical practice, bridging ‘the disintegrative influence of geographical separation’ described by H.G. Wells.
Table 1

Digital health and the End TB Strategy: a history of the future?

Domains*Examples from…
TodayTomorrow
Integrated, patient-centred care and preventionVideo-observed therapyEdible microchips transmitting to mobile electronic devices; registering the gesture of a specific patient taking a given pill
Databasing laboratory results and patient parametersConnected diagnosticsTracking disease biomarkers via ‘wearables’
Point of care testingDigitisation of biological material (genome, chemistry), integration of data from multiple sources and remote consultation of experts
Standardising anti-TB medicationIntimate monitoring of biomarkers to optimise care
Internet-based reference and eLearning contentDecision aids informed by Big Data; advanced machine learning techniquesAlerting people of exposure risks from real-time analysis of environmental and other data
Bold policies and supportive systemsData management shifts from paper to electronic systemsSeamless interoperability of computer networks and cloud-based data sets
GIS mapping of patients and service providersReal-time localisation of individualsUnique identifiers which incorporate biomarker data
Conditional cash transfers as an extension of micro-financingRewarding behaviour linked to therapeutic effectPersonal genome data as a patient asset
Strengthening logistic information systemsReal-time tracking of equipment and consumables
Intensified research and innovationDigitising data from studiesMining data sets In silico modelling of interventions using new drugs and vaccines
eLearning to build capacity in conducting and translating research

*Corresponding to the three pillars of the WHO End TB Strategy.3

TB, tuberculosis.

Digital health and the End TB Strategy: a history of the future? *Corresponding to the three pillars of the WHO End TB Strategy.3 TB, tuberculosis. These technological advances will give new meaning to personalised medicine, be it for the itinerant individual as for patients with limited mobility. ICT is also breaking new ground on other fronts important for patient-centred care, such as equity, human rights and patient empowerment. For instance, unique biometric identifiers have been assigned to over 900 million individuals in record time in India showing how digital technology can bridge inequalities and help the masses accede to their entitlements.10 Legitimate concerns about privacy and civil liberties—particularly as computing moves from hard discs to the cloud—have more recently become tempered by the viewpoint that people could profit directly from the asset value of their personal data.11 New mechanisms would need to be created to ensure that this can happen safely. Leading minds in science and technology are voicing caution about the prospect of artificial intelligence being allowed to take the driving seat of processes hitherto controlled by humans.12 This may sound surreal for some, but the risk of losing sight of patients when medicine becomes too high tech is already conceivable to many practitioners. The national eHealth strategies that countries are implementing could broaden the discourse of how health priorities can match appropriate digital technologies while avoiding such traps.13 Anti-TB efforts are advantageously positioned to integrate new digital health methods. Such experience could benefit other health and social issues. Tuberculosis is firmly rooted within topical agendas as disparate as antimicrobial resistance, lifestyle risks and social determinants. It remains a concern for rich and poor countries alike. There is an entrepreneurial worldwide network of country-based public and private actors, technical agencies and donors which has shown vigorous leadership in adopting creative solutions for tuberculosis prevention and care. Proof of this is the pace and scale with which novel diagnostics and medicines are being rolled out in several countries.14 Moreover, a mature culture of patient-based monitoring within national tuberculosis programmes provides a structured framework on which innovative interventions in surveillance and care could be grafted and evaluated for effectiveness and barriers. Bold investments in digital health products could revolutionise tuberculosis prevention and care as the disease and the technology evolve within the fabric of the global interconnectedness that Wells predicted for our future.
  4 in total

1.  Effect of a clinical decision support system on early action on immunological treatment failure in patients with HIV in Kenya: a cluster randomised controlled trial.

Authors:  Tom Oluoch; Abraham Katana; Daniel Kwaro; Xenophon Santas; Patrick Langat; Samuel Mwalili; Kimeu Muthusi; Nicky Okeyo; James K Ojwang; Ronald Cornet; Ameen Abu-Hanna; Nicolette de Keizer
Journal:  Lancet HIV       Date:  2015-12-17       Impact factor: 12.767

2.  WHO's new end TB strategy.

Authors:  Mukund Uplekar; Diana Weil; Knut Lonnroth; Ernesto Jaramillo; Christian Lienhardt; Hannah Monica Dias; Dennis Falzon; Katherine Floyd; Giuliano Gargioni; Haileyesus Getahun; Christopher Gilpin; Philippe Glaziou; Malgorzata Grzemska; Fuad Mirzayev; Hiroki Nakatani; Mario Raviglione
Journal:  Lancet       Date:  2015-03-24       Impact factor: 79.321

3.  Principles and framework for eHealth strategy development.

Authors:  Richard E Scott; Maurice Mars
Journal:  J Med Internet Res       Date:  2013-07-30       Impact factor: 5.428

4.  Electronic recording and reporting system for tuberculosis in China: experience and opportunities.

Authors:  Fei Huang; ShiMing Cheng; Xin Du; Wei Chen; Fabio Scano; Dennis Falzon; Lixia Wang
Journal:  J Am Med Inform Assoc       Date:  2013-12-10       Impact factor: 4.497

  4 in total
  1 in total

Review 1.  Use of Digital Technology to Enhance Tuberculosis Control: Scoping Review.

Authors:  Yejin Lee; Mario C Raviglione; Antoine Flahault
Journal:  J Med Internet Res       Date:  2020-02-13       Impact factor: 5.428

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.